{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:23:58Z","timestamp":1793823838033,"version":"4.6.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jonah\u2019s Just Begun,","award":["Improving brain delivery of adeno-associated gene therapy vectors for the treatment of MPS IIIC"],"award-info":[{"award-number":["Improving brain delivery of adeno-associated gene therapy vectors for the treatment of MPS IIIC"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mucopolysaccharidosis IIIC (MPSIIIC) is one of four Sanfilippo diseases sharing clinical symptoms of severe cognitive decline and shortened lifespan. The missing enzyme, heparan sulfate acetyl-CoA: \u03b1-glucosaminide-N-acetyltransferase (HGSNAT), is bound to the lysosomal membrane, therefore cannot cross the blood-brain barrier or diffuse between cells. We previously demonstrated disease correction in MPSIIIC mice using an Adeno-Associated Vector (AAV) delivering HGSNAT via intraparenchymal brain injections using an AAV2 derived AAV-truetype (AAV-TT) serotype with improved distribution over AAV9.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Here, intraparenchymal AAV was delivered in sheep using catheters or Hamilton syringes, placed using Brainlab cranial navigation for convection enhanced delivery, to reduce proximal vector expression and improve spread.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Hamilton syringes gave improved AAV-GFP distribution, despite lower vector doses and titres. AAV-TT-GFP displayed moderately better transduction compared to AAV9-GFP but both serotypes almost exclusively transduced neurons. Functional HGSNAT enzyme was detected in 24-37% of a 140g gyrencephalic sheep brain using AAV9-HGSNAT with three injections in one hemisphere.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Despite variabilities in volume and titre, catheter design may be critical for efficient brain delivery. These data help inform a clinical trial for MPSIIIC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-023-04208-1","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T05:10:10Z","timestamp":1688533810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Intraparenchymal convection enhanced delivery of AAV in sheep to treat Mucopolysaccharidosis IIIC"],"prefix":"10.1186","volume":"21","author":[{"given":"Claire","family":"O\u2019Leary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Forte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia L.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Saam","family":"Youshani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Dyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"Wellby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina N.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha J.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Jolinon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Stacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Henckaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Kamaly-Asl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"Bigger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"4208_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2147\/TACG.S57672","volume":"8","author":"AO Fedele","year":"2015","unstructured":"Fedele AO. Sanfilippo syndrome: causes, consequences, and treatments. Appl Clin Genet. 2015;8:269\u201381.","journal-title":"Appl Clin Genet"},{"issue":"1","key":"4208_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13023-017-0675-4","volume":"12","author":"A Ghosh","year":"2017","unstructured":"Ghosh A, et al. Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III. Orphanet J Rare Dis. 2017;12(1):117.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"4208_CR3","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1093\/brain\/awy126","volume":"141","author":"J Tordo","year":"2018","unstructured":"Tordo J, et al. A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency. Brain. 2018;141(7):2014\u201331.","journal-title":"Brain"},{"issue":"6","key":"4208_CR4","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1089\/hum.2013.238","volume":"25","author":"M Tardieu","year":"2014","unstructured":"Tardieu M, et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial. Human Gene Ther. 2014;25(6):506\u201316.","journal-title":"Human Gene Ther"},{"issue":"9","key":"4208_CR5","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","volume":"16","author":"M Tardieu","year":"2017","unstructured":"Tardieu M, et al. Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial. Lancet Neurol. 2017;16(9):712\u201320.","journal-title":"Lancet Neurol"},{"issue":"9","key":"4208_CR6","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1089\/hum.2018.189","volume":"30","author":"AL Gray","year":"2019","unstructured":"Gray AL, et al. An improved adeno-associated virus vector for neurological correction of the mouse model of Mucopolysaccharidosis IIIA. Human Gene Ther. 2019;30(9):1052\u201366.","journal-title":"Human Gene Ther"},{"key":"4208_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.965089","author":"SR Wood","year":"2022","unstructured":"Wood SR, Bigger BW. Delivering gene therapy for mucopolysaccharide diseases. Front Mol Biosci. 2022. https:\/\/doi.org\/10.3389\/fmolb.2022.965089.","journal-title":"Front Mol Biosci"},{"issue":"17\u201318","key":"4208_CR8","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1089\/hum.2022.170","volume":"33","author":"A McElroy","year":"2022","unstructured":"McElroy A, et al. Redosing adeno-associated virus gene therapy to the central nervous system. Human Gene Ther. 2022;33(17\u201318):889\u201392.","journal-title":"Human Gene Ther"},{"issue":"2","key":"4208_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s13311-017-0520-4","volume":"14","author":"AM Mehta","year":"2017","unstructured":"Mehta AM, Sonabend AM, Bruce JN. Convection-enhanced delivery. Neurotherapeutics. 2017;14(2):358\u201371.","journal-title":"Neurotherapeutics"},{"issue":"5","key":"4208_CR10","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3171\/JNS\/2008\/109\/11\/0874","volume":"109","author":"V Varenika","year":"2008","unstructured":"Varenika V, et al. Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. J Neurosurg. 2008;109(5):874\u201380.","journal-title":"J Neurosurg"},{"issue":"2","key":"4208_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/bpa.12082","volume":"24","author":"NU Barua","year":"2014","unstructured":"Barua NU, Gill SS, Love S. Convection-enhanced drug delivery to the brain: therapeutic potential and neuropathological considerations. Brain Pathol. 2014;24(2):117\u201327.","journal-title":"Brain Pathol"},{"issue":"4","key":"4208_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2174\/157016312803305951","volume":"9","author":"AI Mehta","year":"2012","unstructured":"Mehta AI, et al. Convection enhanced delivery of macromolecules for brain tumors. Curr Drug Discov Technol. 2012;9(4):305\u201310.","journal-title":"Curr Drug Discov Technol"},{"key":"4208_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.wneu.2017.07.098","volume":"106","author":"EW Sankey","year":"2017","unstructured":"Sankey EW, Butler E, Sampson JH. Accuracy of novel computed tomography-guided frameless stereotactic drilling and catheter system in human cadavers. World Neurosurgery. 2017;106:757\u201363.","journal-title":"World Neurosurgery"},{"issue":"9","key":"4208_CR14","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.7150\/thno.22852","volume":"8","author":"M Pelekanos","year":"2018","unstructured":"Pelekanos M, et al. Establishing sheep as an experimental species to validate ultrasound-mediated blood-brain barrier opening for potential therapeutic interventions. Theranostics. 2018;8(9):2583\u2013602.","journal-title":"Theranostics"},{"issue":"5","key":"4208_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.tins.2013.01.006","volume":"36","author":"K Zilles","year":"2013","unstructured":"Zilles K, Palomero-Gallagher N, Amunts K. Development of cortical folding during evolution and ontogeny. Trends in Neurosciences. 2013;36(5):275\u201384.","journal-title":"Trends in Neurosciences"},{"issue":"1","key":"4208_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/1073858414521870","volume":"21","author":"DS Ojala","year":"2015","unstructured":"Ojala DS, Amara DP, Schaffer DV. Adeno-associated virus vectors and neurological gene therapy. Neuroscientist. 2015;21(1):84\u201398.","journal-title":"Neuroscientist"},{"key":"4208_CR17","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2147\/IJN.S61288","volume":"9","author":"CT Lu","year":"2014","unstructured":"Lu CT, et al. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomed. 2014;9:2241\u201357.","journal-title":"Int J Nanomed"},{"issue":"2","key":"4208_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1517\/17425247.2015.966682","volume":"12","author":"DA Wolf","year":"2015","unstructured":"Wolf DA, et al. Gene therapy for neurologic manifestations of mucopolysaccharidoses. Expert Opin Drug Deliv. 2015;12(2):283\u201396.","journal-title":"Expert Opin Drug Deliv"},{"key":"4208_CR19","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.omtm.2020.04.012","volume":"17","author":"C Hinderer","year":"2020","unstructured":"Hinderer C, et al. Translational feasibility of lumbar puncture for intrathecal AAV administration. Mol Ther Methods Clin Dev. 2020;17:969\u201374.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4208_CR20","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.omtm.2020.04.001","volume":"17","author":"K Bey","year":"2020","unstructured":"Bey K, et al. Intra-CSF AAV9 and AAVrh10 administration in nonhuman primates: promising routes and vectors for which neurological diseases? Mol Ther Methods Clin Dev. 2020;17:771\u201384.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4208_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.omtm.2018.12.001","volume":"13","author":"K Ohno","year":"2018","unstructured":"Ohno K, et al. Kinetics and MR-based monitoring of AAV9 vector delivery into cerebrospinal fluid of nonhuman primates. Mol Ther Methods Clin Dev. 2018;13:47\u201354.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"4208_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/hum.2017.026","volume":"29","author":"C Hinderer","year":"2017","unstructured":"Hinderer C, et al. Evaluation of intrathecal routes of administration for adeno-associated viral vectors in large animals. Human Gene Ther. 2017;29(1):15\u201324.","journal-title":"Human Gene Ther"},{"issue":"2","key":"4208_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/mt.2013.266","volume":"22","author":"L Samaranch","year":"2014","unstructured":"Samaranch L, et al. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol Ther. 2014;22(2):329\u201337.","journal-title":"Mol Ther"},{"issue":"22","key":"4208_CR24","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1093\/hmg\/ddm223","volume":"16","author":"A Fraldi","year":"2007","unstructured":"Fraldi A, et al. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Hum Mol Genet. 2007;16(22):2693\u2013702.","journal-title":"Hum Mol Genet"},{"issue":"8","key":"4208_CR25","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1172\/JCI66778","volume":"123","author":"V Haurigot","year":"2013","unstructured":"Haurigot V, et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest. 2013;123(8):3254\u201371.","journal-title":"J Clin Invest"},{"key":"4208_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.omtm.2019.08.003","volume":"15","author":"S Prabhakar","year":"2019","unstructured":"Prabhakar S, et al. Long-term therapeutic efficacy of intravenous AAV-mediated hamartin replacement in mouse model of tuberous sclerosis Type 1. Mol Ther Methods Clin Dev. 2019;15:18\u201326.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10","key":"4208_CR27","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.ymthe.2018.07.015","volume":"26","author":"NL Mitchell","year":"2018","unstructured":"Mitchell NL, et al. Longitudinal in vivo monitoring of the CNS demonstrates the efficacy of gene therapy in a sheep model of CLN5 Batten disease. Mol Ther. 2018;26(10):2366\u201378.","journal-title":"Mol Ther"},{"issue":"3","key":"4208_CR28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1089\/hum.2017.163","volume":"29","author":"HL Gray-Edwards","year":"2018","unstructured":"Gray-Edwards HL, et al. Adeno-associated virus gene therapy in a sheep model of Tay-Sachs disease. Human Gene Ther. 2018;29(3):312\u201326.","journal-title":"Human Gene Ther"},{"issue":"3","key":"4208_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ymgme.2016.05.006","volume":"118","author":"SA Jones","year":"2016","unstructured":"Jones SA, et al. A phase 1\/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA. Mol Genet Metab. 2016;118(3):198\u2013205.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"4208_CR30","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1592\/phco.29.7.832","volume":"29","author":"AM Cook","year":"2009","unstructured":"Cook AM, et al. Intracerebroventricular administration of drugs. Pharmacotherapy. 2009;29(7):832\u201345.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"4208_CR31","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jneumeth.2010.10.010","volume":"194","author":"N Carty","year":"2010","unstructured":"Carty N, et al. Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. J Neurosci Methods. 2010;194(1):144\u201353.","journal-title":"J Neurosci Methods"},{"issue":"6","key":"4208_CR32","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1227\/01.NEU.0000334052.60634.84","volume":"63","author":"N Luther","year":"2008","unstructured":"Luther N, et al. Intraparenchymal and intratumoral interstitial infusion of anti-glioma monoclonal antibody 8H9. Neurosurgery. 2008;63(6):1166\u201374.","journal-title":"Neurosurgery"},{"issue":"9","key":"4208_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1096","volume":"8","author":"KN Russell","year":"2018","unstructured":"Russell KN, et al. Computed tomography provides enhanced techniques for longitudinal monitoring of progressive intracranial volume loss associated with regional neurodegeneration in ovine neuronal ceroid lipofuscinoses. Brain Behav. 2018;8(9): e01096.","journal-title":"Brain Behav"},{"issue":"1","key":"4208_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.nbd.2008.06.004","volume":"32","author":"MJ Oswald","year":"2008","unstructured":"Oswald MJ, et al. Location and connectivity determine GABAergic interneuron survival in the brains of South Hampshire sheep with CLN6 neuronal ceroid lipofuscinosis. Neurobiol Dis. 2008;32(1):50\u201365.","journal-title":"Neurobiol Dis"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04208-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04208-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04208-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T05:12:09Z","timestamp":1688533929000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04208-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4208"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04208-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,5]]},"assertion":[{"value":"24 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols were approved by the Lincoln University Animal Ethics Committee (Lincoln University Animal Ethics applications 213 and 423).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Delivery of HGSNAT using AAV to MPSIIIC is the subject of a patent held by BB, COL and EH. BB is a consultant and grant holder for AVROBIO, Orchard Therapeutics and Phoenix Nest. BB and COL received payments from Phoenix Nest for previous MPSIIIC work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"437"}}